Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

  • End date
    Dec 26, 2027
  • participants needed
  • sponsor
    Stanford University
Updated on 26 July 2021
cell transplantation


The purpose of this study is to determine the safety of a cell therapy, T-allo10, after depleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).

The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D) administered after infusion of depleted-HSCT in children and young adults with hematologic malignancies.

A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of depleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution.

All participants on this study must be enrolled on another study: NCT04249830

Condition Blood disorder, hematologic disorder, blood disorders, hematologic disorders, hematologic disease, blood diseases, hematological disease, blood dyscrasias, blood dyscrasia, haematological disorders
Treatment Allogeneic stem cell transplant, CliniMACS Prodigy System, T-allo10 cells addback
Clinical Study IdentifierNCT04640987
SponsorStanford University
Last Modified on26 July 2021


Yes No Not Sure

Inclusion Criteria

\. Age > 1 months (with minimum weight of 10 Kg) and < 45 years
\. Patients deemed eligible for allogeneic HSCT under the originating study, NCT 04249830
\. Patients with life-threatening hematological malignancies for which HSCT has been
High-risk ALL in 1st CR, ALL in 2nd or subsequent CR
High-risk AML in 1st CR, AML in 2nd or subsequent CR
Myelodysplastic syndrome
JMML (Juvenile myelomonocytic leukemia)
Non-Hodgkin lymphomas in 2nd or subsequent CR
Other hematologic malignancies eligible for stem cell transplantation per institutional standard
\. All subjects 18 years of age must be able to give informed consent, or adults lacking capacity to consent must have a LAR available to provide consent. For subjects <18 years old their LAR (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriate
Inclusion criteria prior to T-allo10 infusion
Patient already received depleted-HSCT and has myeloid engraftment
Absence of active grade II aGvHD requiring >0.5 mg/Kg of steroids or any diagnosis of grade III/IVaGvHD

Exclusion Criteria

Not eligible to receive HSCT on NCT04249830
Received another investigational agent within 30 days of enrollment
Pregnancy (positive serum or urine beta-HCG) within 7 days of MNC donation
Patient or donor is not willing or able to undergo an additional non-mobilized apheresis for collection of MNC prior to donation of cells for participation in NCT04249830
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note